The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Bourgoin early development hub broadens offerings for oral solid dose formulations
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Subscribe To Our Newsletter & Stay Updated
